Greenwich LifeSciences Q4 2023 Earnings Report $12.39 -0.13 (-1.04%) (As of 12/20/2024 05:31 PM ET) Earnings HistoryForecast Greenwich LifeSciences EPS ResultsActual EPS-$0.21Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/AGreenwich LifeSciences Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AGreenwich LifeSciences Announcement DetailsQuarterQ4 2023Date4/15/2024TimeN/AConference Call ResourcesGLSI Earnings History Could This Tiny Device Help You Make an Extra $30k a Year? (Ad)I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more than $9 trillion. That’s nearly 10 times more money than the market caps of Tesla… SpaceX… PayPal… Neuralink… and X… COMBINED.Click here to see the details because I believe a lot of people will get rich. Greenwich LifeSciences Earnings HeadlinesGreenwich LifeSciences Partners With Breast C...November 26, 2024 | benzinga.comGreenwich LifeSciences Partners with GIM in ItalyNovember 26, 2024 | globenewswire.comTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… December 21, 2024 | Crypto 101 Media (Ad)Greenwich LifeSciences Provides Update on Corporate EventsNovember 18, 2024 | globenewswire.comGreenwich LifeSciences (NASDAQ:GLSI) Stock Quotes, Forecast and News SummaryOctober 6, 2024 | benzinga.comGreenwich LifeSciences, Inc. (NASDAQ:GLSI) insiders seem bullish, own 55% and have been buying more recentlySeptember 12, 2024 | finance.yahoo.comSee More Greenwich LifeSciences Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Greenwich LifeSciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Greenwich LifeSciences and other key companies, straight to your email. Email Address About Greenwich LifeSciencesGreenwich LifeSciences (NASDAQ:GLSI), a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery. The company was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. Greenwich LifeSciences, Inc. was incorporated in 2006 and is headquartered in Stafford, Texas.View Greenwich LifeSciences ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles History Hints at a Rebound for Toll Brothers After EarningsAlibaba Stock: Why Earnings Make It a Buy Despite the Recent DipMercadoLibre Down 23% After Missed Earnings: Time to Buy the Dip?Roblox Stock Soars 22% After Q3 Earnings – A Turning Point Ahead?Apple Earnings - When Really Good Just Isn’t Good Enough Roblox Stock Set for More Gains After Strong Earnings ReportAmazon: Why Analysts Think It's a Solid Buy Ahead of Earnings Upcoming Earnings Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
